I am a
Home I AM A Search Login

Papers of the Week

Papers: 3 Oct 2020 - 9 Oct 2020

Human Studies, Pharmacology/Drug Development


2020 Oct 07

Pain Ther

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine.


Silberstein SD, Diener H-C, Dodick DW, Adams A M, Degryse RE, Lipton RB
Pain Ther. 2020 Oct 07.
PMID: 33026630.


The phase 3 PREEMPT trials demonstrated efficacy and tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. OnabotulinumtoxinA significantly reduced headache frequency from baseline vs. placebo at 24 weeks; however, this measure may not fully capture the benefits of treatment. We evaluated the impact of onabotulinumtoxinA on patient-reported outcomes according to headache responder status.